September 29, 2026

An Invitation to Argentina

Retina specialists preview the clinical and surgical program planned for the Argentine Society of Retina and Vitreous (Sociedad Argentina de Retina y Vítreo, or SARyV), November 5-7 in Ushuaia, Argentina.

September 29, 2026

Ultrawidefield Imaging in Sickle Cell Retinopathy

Adrienne Scott, MD, discusses a prospective case series evaluating ultrawidefield imaging of macular and peripheral pathology in patients with sickle cell disease.

September 29, 2026

The Regulatory Path Ahead for Axpaxli

Peter Kaiser, MD, explains how the SOL-1 results and discussions with the FDA are shaping Ocular Therapeutix's planned NDA submission.

September 29, 2026

Inside the ARCHER II Trial

Ashkan Abbey, MD, explains how phase 2 findings informed the design and patient population of the phase 3 vonaprument trial in geographic atrophy.

September 29, 2026

Encelto Shows Outer Retinal Preservation in MacTel

Jay Chhablani, MD, reviews a post hoc analysis showing effects on ellipsoid zone and outer nuclear layer measures, along with a modest reduction in cavitation volume.

September 29, 2026

Turning Structural OCT Into Functional Data

Roger Goldberg, MD, MBA, discusses OCT-F, a new AI-enabled method that uses structural OCT to estimate retinal sensitivity in geographic atrophy.

September 29, 2026

The Road Ahead for Optogenetics

Allen C. Ho, MD, FACS, discusses the FDA’s acceptance of the BLA for MCO-010 and the potential of optogenetic therapy for severe vision loss in retinitis pigmentosa.

September 28, 2026

New Gildeuretinol Findings From Retina Society

Kenneth C. Fan, MD, MBA, and Baruch D. Kuppermann, MD, PhD, presented TEASE findings on the safety and efficacy of oral gildeuretinol and discussed the phase 3 NORTHSTAR trial.

September 28, 2026

Statin Use Linked to Lower PVR Risk

A retrospective study presented at Retina Society 2026 found lower rates of PVR and complex reoperation after RD repair among patients taking systemic statins.

September 28, 2026

Sura-vec Shows Durable Effect at 3 Years

Nikolas London, MD, MS, FACS, discusses long-term findings with gene therapy ABBV-RGX-314 in patients with nonproliferative diabetic retinopathy.

September 28, 2026

PDS May Reduce Treatment Burden in High-Need Patients

Yasha Modi, MD, discusses phase 4 data on the port delivery system in patients with nAMD who previously required frequent anti-VEGF injections.

September 28, 2026

Long-Term PDS Data Show Sustained Disease Control

Jeremy Wolfe, MD, MS, discusses long-term vision, fluid control, safety, and refill intervals with the port delivery system for nAMD.

September 27, 2026

Star-DDS: A New Approach to Aflibercept Durability

Jennifer Kang-Mieler, PhD, discusses a biodegradable drug-delivery platform designed to provide sustained intravitreal aflibercept delivery for 6 months or longer.

September 26, 2026

Timing of Stage 2 ROP May Help Identify High-Risk Eyes

In a study presented at Retina Society, stage 2 diagnosis at an earlier postmenstrual age was associated with higher treatment rates and a greater proportion of zone I disease.

September 26, 2026

New Tiespectus Data in Treatment-Naïve nAMD

Diana V. Do, MD, reviews phase 1/2a findings for the bispecific Tie2 agonist and VEGF inhibitor, presented at Retina Society 2026.

September 26, 2026

The Changing Economics of Retina

Twenty years of Medicare data show rising procedure volume, changing treatment patterns, and a 32% decline in inflation-adjusted reimbursement.

September 26, 2026

Avacincaptad Pegol and Anti-VEGF in Real-World Practice

An IRIS Registry analysis of more than 13,000 eyes found that concomitant anti-VEGF use for nAMD or CNV did not substantially alter complement inhibitor treatment.

September 25, 2026

Tracking Fluid Resolution After Photodynamic Therapy

A single-patient analysis found that more than half of estimated subretinal fluid volume resolved within 9 days of half-fluence PDT for chronic CSCR.

September 25, 2026

Epiretinal Membrane Removal May Reduce Injection Burden in nAMD

In a small retrospective study, two-thirds of patients stopped or reduced anti-VEGF injections following surgery.

September 25, 2026

Study Supports 30-Second Chlorhexidine Protocol for IVI

Aqueous chlorhexidine 0.05% significantly reduced conjunctival bacteria within 30 seconds, supporting a shorter antisepsis protocol using a less irritating alternative to povidone-iodine.

September 25, 2026

A First Look at the LUGANO Data

Charles C. Wykoff, MD, PhD, and Carl Regillo, MD, FACS, examine phase 3 EYP-1901 findings presented for the first time at Retina Society 2026.

September 25, 2026

New Data on Laru-Zova in XLRP

Phase 2 DAWN results provide additional evidence on safety and visual function as the laru-zova program advances through the pivotal VISTA trial.

September 25, 2026

Four-Year Data Show Durable MCO-010 Effect

Long-term follow-up of RESTORE participants shows sustained visual acuity improvements after a single intravitreal administration of the optogenetic therapy.